Introduction

Datamonitor has estimated that there were approximately 4.5 million cases of diagnosed active epilepsy in 2010 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). Almost half of this patient population lives in the US. Datamonitor expects prevalence rates to remain constant over the forecast period (2010–20). As such, the aging populations in th

Features and benefits

• Gain insight to market potential, including a robust 10-year epidemiology forecast of prevalent cases of diagnosed active epilepsy.
• Understand the key epidemiologic risk factors associated with epilepsy.

Highlights

Datamonitor expects an increase in diagnosed active epilepsy cases in the next decade in the seven major markets as a result of an increase in populations.

Chronic epilepsy can result in brain damage, disability, and a low quality of life causing high social and economic burden

Your key questions answered

• What are the most robust epidemiologic studies for diagnosed active epilepsy prevalence data?
• How will the patient population change over the next decade in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK)?
• How do changes in population structure and risk factors affect the trend in prevalent diagnosed active epilepsy cases?